Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs 3M Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.78 (market cap $29.60B), while 3M Company trades at $183.16 (market cap $94.44B). The key difference: 3M Company is far larger — about 3.2× Alnylam Pharmaceuticals, Inc.'s market cap, and 3M Company pays a 1.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MMM | |
|---|---|---|
Market Cap | $29.60B | $94.44B |
Sector | Health | Industrials |
52-Week High | $491.22 | $183.13 |
52-Week Low | $205.48 | $141.10 |
Enterprise Value | $27.56B | $103.67B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
MMM trades at $182.04, showing modest daily weakness but maintaining a bullish technical trend with strong support near $181. Recent Q2 2026 earnings beat expectations with EPS of $2.40, driven by 5.4% organic growth and margin expansion, leading to raised full-year guidance. The stock's valuation remains elevated with a P/E of 32.53, while analyst sentiment is mixed with a near-even split between buy and hold ratings.
The outlook is cautiously optimistic, supported by operational improvements and innovation in high-growth verticals like Safety & Industrial. Key risks include litigation liabilities and macroeconomic pressures. Upside potential exists if execution continues to surpass expectations, but current prices may already reflect near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
